Biotech with Alzheimer's Focus Makes Progress on Several Fronts
Companies / BioTech Jul 19, 2017 - 02:17 PM GMTBy: TLSReport
In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development.
Among ProMIS Neurosciences Inc.'s (PMN:TSE) "key accomplishments" in the quarter, the company noted it expanded its potentially "best in class amyloid-beta (Aβ) portfolio for Alzheimer's disease," according to a July 10 news release. In its oral presentation, the company stressed its emphasis on the "best in class" goal, noting that even though Biogen Inc.'s (BIIB:NASDAQ) aducanumab will be "first in class" and is progressing well in development, the ProMIS compound could be more selective and possess greater patient benefits.
Advancements included designating "PMN350 as second validated product lead [based on] in vivo data and biologic evidence of neuronal protection against toxic Aβ oligomers," as well as continuing efforts to validate "additional antibody product candidates against various Aβ epitope targets [with] data anticipated in coming months."
ProMIS also noted the identification of an "epitope target on TDP43 (implicated in ALS and frontotemporal dementia)," and submission of a "provisional patent" to the U.S. Patent Office.
The company is also progressing on cohort studies designed to "explore opportunities for precision medicine" in the treatment of Alzheimer's disease.
In addition, the company continues working to identify "specific targets on alpha-synuclein (Parkinson's and Lewy body dementia) and tau (Alzheimer's disease)."
"We are pleased with the continued progress at ProMIS and remain confident that our monoclonal antibody programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta may lead to best in class therapies and significant long-term value creation," the company executive chairman, Eugene Williams, stated in the release.
Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.
Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.
